On November 16, 2026, The New England Journal of Medicine published the full results of STEP Young, a Phase 3 trial of semaglutide, the active ingredient in Wegovy, in children 6 to under 12 years old with obesity. Novo Nordisk sponsored the trial, reported headline results in September 2026 and presented the full data, including the 104-week results, at ObesityWeek 2026 in Washington, D.C. At 68 weeks, body-mass index (BMI) fell 13.5% with semaglutide and rose 2.7% with placebo, counting every child whether or not they stayed on treatment.
Wegovy is approved in the United States for weight management from age 12. Novo states that semaglutide is not approved in the United States for children under 12.
The trial
STEP Young was double-blind and placebo-controlled, with sites in ten countries, the United States among them. It randomly assigned 167 children in a 2:1 ratio, 112 to semaglutide and 55 to placebo, for 104 weeks of treatment followed by a 7-week washout. Both groups received counseling on a reduced-calorie diet and increased physical activity. More than 85% of the children had class II or III obesity at the start.
The primary endpoint was the percent change in BMI at week 68, and the confirmatory secondary endpoint was a move to a lower BMI category. Trials in children measure BMI rather than body weight because children are still growing. Obesity in a child is a BMI at or above the 95th percentile for age and sex on the growth charts of the Centers for Disease Control and Prevention (CDC), and classes II and III start at 120% and 140% of that threshold.
Results at 68 weeks
Novo reports two analyses. The treatment regimen estimand counts every child, whether or not they stayed on treatment, and is the primary analysis. The efficacy estimand assumes every child stayed on treatment.
- BMI change, counting every child: -13.5% with semaglutide and +2.7% with placebo, a difference of 16.2 percentage points (95% confidence interval 12.9 to 19.4).
- BMI change, assuming every child stayed on treatment: -17.4% with semaglutide and +2.2% with placebo.
- Lower BMI category: 79% of children on semaglutide and 23% on placebo (odds ratio 7.8), as observed in the trial.
- Below the obesity threshold: 38% on semaglutide and 2% on placebo, as observed, or 40.4% and 0% under the efficacy estimand.
- BMI down at least 10%: 74.7% on semaglutide and 4.3% on placebo, as observed, or 78.7% and 0% under the efficacy estimand.
Results at 104 weeks
Counting every child, BMI was 9.4% below baseline with semaglutide and 8.4% above it with placebo at week 104, a difference of 17.8 percentage points. Under the efficacy estimand the figures were -14.0% and +5.7%. The mean reduction on semaglutide was smaller than at week 68, while the gap with placebo held. In the semaglutide group, 33.3% of children were below the obesity threshold at week 104, against 2.4% on placebo. Novo notes that the week-104 analyses were not adjusted for multiple comparisons, so they cannot support firm conclusions.
Safety
Adverse events occurred in 96% of children on semaglutide and 93% on placebo. Gastrointestinal events were the most common, occurred more often with semaglutide and led one child on semaglutide to stop treatment. Novo says the safety profile matched earlier semaglutide trials in children and adults, and that it identified no safety concerns for growth or pubertal development.
Earlier GLP-1 trials in children
Novo has run earlier trials of glucagon-like peptide-1 (GLP-1) receptor agonists in young people with obesity, and two of them, both published in The New England Journal of Medicine, are the nearest comparisons. Eli Lilly published an adolescent trial of tirzepatide a day before STEP Young.
- STEP TEENS (2022) tested semaglutide in 201 adolescents 12 to under 18. At 68 weeks, BMI fell 16.1% with semaglutide and rose 0.6% with placebo in the primary analysis. It is the trial behind Wegovy's adolescent indication.
- SCALE Kids (2025) tested liraglutide, the active ingredient in Saxenda, in 82 children 6 to under 12. At 56 weeks, BMI fell 5.8% with liraglutide and rose 1.6% with placebo, while body weight rose in both groups (1.6% and 10.0%) as the children grew. Saxenda's label, as revised in February 2026, covers pediatric patients from age 12 who weigh more than 60 kg.
- SURMOUNT-ADOLESCENTS (published in JAMA on November 15, 2026) tested tirzepatide, a dual GIP and GLP-1 receptor agonist and the active ingredient in Zepbound, in 160 adolescents 12 to under 18. At 72 weeks, BMI fell 18.5% with tirzepatide and rose 0.5% with placebo in the primary analysis. Zepbound is indicated for adults.
The four trials enrolled different age groups, ran for different lengths and tested different drugs, so their results cannot rank the drugs against each other.
What comes next
Novo's November 16 release does not say whether or when it will ask the Food and Drug Administration (FDA) to extend Wegovy's label to children under 12. ClinicalTrials.gov lists the study as active but not recruiting, with completion estimated for December 2026.
The results apply to Novo's product as tested in the trial. They do not extend to research-grade semaglutide, a separate material sold for laboratory research and not approved for any use in people.
Sources
- Jastreboff and colleagues, Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age, New England Journal of Medicine, November 16, 2026: enrollment, the 68-week and 104-week BMI results and adverse events.
- Novo Nordisk, STEP Young results at ObesityWeek 2026, November 16, 2026: both estimands at 68 and 104 weeks, baseline obesity classes, the safety statement and US approval status.
- ClinicalTrials.gov, NCT05726227: trial countries, status and estimated completion.
- Weghuber and colleagues, Once-Weekly Semaglutide in Adolescents with Obesity, New England Journal of Medicine, 2022: STEP TEENS.
- Fox and colleagues, Liraglutide for Children 6 to <12 Years of Age with Obesity, New England Journal of Medicine, 2025: SCALE Kids.
- Kelly and colleagues, Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial, JAMA, November 15, 2026: enrollment and the 72-week BMI results.
- Eli Lilly, ObesityWeek 2026 presentations, November 14, 2026: Zepbound's indication.
- Saxenda prescribing information, DailyMed: the pediatric indication.
Sources checked November 18, 2026.